US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

WisdomTree Asia Local Debt Fund

44.39

+0.0000

Volume:- -

Turnover:- -

Market Cap:22.20M

PE:16.75

High:44.39

Open:44.39

Low:44.39

Close:44.39

Loading ...

Overview Company News Filings

Poxel Announces its Financial Calendar for 2025

Citi Sticks to Its Buy Rating for ALD SA (3AL)

Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025

Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment

Great week for Ampol Limited (ASX:ALD) institutional investors after losing 14% over the previous year

Simply Wall St.

Adisyn acquires 2D Generation, forging foothold in booming semiconductor market

Ampol (ASX:ALD) Might Have The Makings Of A Multi-Bagger

Simply Wall St.

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Availability of Poxel’s 2024 Half-Year Financial Report

Adisyn completes due diligence of 2D Generation, set to tap into hot semiconductor market

ACM Research Strengthens Atomic Layer Deposition Portfolio with Qualification of Thermal and Plasma-Enhanced ALD Furnace Tools

Returns At Ampol (ASX:ALD) Are On The Way Up

Simply Wall St.

Are Ampol Limited's (ASX:ALD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Simply Wall St.

Poxel Announces Results from November 28, 2024 Annual General Meeting

Adisyn’s 2D Generation is in the global race to bring graphene into advanced semiconductors

Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents

Press Release: Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update

This High-Flying Stock Just Became a Better Buy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALD/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","market":"US","secType":"STK","nameCN":"WisdomTree Asia Local Debt Fund","latestPrice":44.39,"timestamp":1567195200000,"preClose":44.39,"halted":0,"volume":0,"delay":0,"floatShares":400000,"shares":500000,"eps":2.65,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-30 16:00:00 EDT","open":44.39,"high":44.39,"low":44.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":2.65,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":44.39,"sharesOutstanding":400000,"nav":44.492139,"aum":17756473.36,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":0.95455,"high":44.39,"amplitude":0,"preClose":44.39,"low":44.39,"week52Low":41.78,"pbRate":"--","week52High":46.6477,"institutionHeld":0,"latestPrice":44.39,"eps":2.65,"divideRate":0.021504,"volume":0,"delay":0,"ttmEps":2.65,"open":44.39,"prevYearClose":44.39},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALD\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2505046651","title":"Poxel Announces its Financial Calendar for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505046651","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505046651?lang=en_us&edition=fundamental","pubTime":"2025-01-24 01:00","pubTimestamp":1737651600,"startTime":"0","endTime":"0","summary":"POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic disorders, today announced its calendar for the publication of financial information for 2025.All corporate information on Poxel, including financial statements, press releases and corporate presentations, is available on the Investors page of the Company’s website.All statements other than statements of historical fact included in this press release about future events are subject to  change without notice and  factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as \"target,\" \"believe,\" \"expect,\" \"aim,\" \"intend,\" \"may,\" \"anticipate,\" \"estimate,\" \"plan,\" \"project,\" \"will,\" \"can have,\" \"likely,\" \"should,\" \"would,\" \"could\" and other words and terms of similar meaning ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-announces-financial-calendar-2025-170000255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ALD","PXXLF"],"gpt_icon":0},{"id":"2505059307","title":"Citi Sticks to Its Buy Rating for ALD SA (3AL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505059307","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505059307?lang=en_us&edition=fundamental","pubTime":"2025-01-23 14:25","pubTimestamp":1737613515,"startTime":"0","endTime":"0","summary":"Citi analyst Harald Hendrikse maintained a Buy rating on ALD SA (3AL – Research Report) today and set a price target of €8.50. The company’s shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-its-buy-rating-for-ald-sa-3al?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-its-buy-rating-for-ald-sa-3al?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"gpt_icon":0},{"id":"2505120969","title":"Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505120969","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505120969?lang=en_us&edition=fundamental","pubTime":"2025-01-22 01:00","pubTimestamp":1737478800,"startTime":"0","endTime":"0","summary":"Poxel announces that a Combined General Meeting will be held on February 11, 2025, at 9:00 a.m. CET and the availability of the preparatory documents. Poxel announces the addition of a new resolution to the agenda in connection with the alert procedure of the statutory auditors in response to the significant uncertainty over the Company's business continuity resulting from the non-adoption of the financial resolutions at the Combined General Meeting held on November 28, 2024. POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic disorders, today informs its shareholders that a Combined General Meeting will be held on February 11, 2025, at 9:00 am CET at the Mercure Lyon Centre Chteau Perrache Hotel, located at 12 Cours de Verdun-Rambaud Esplanade de la Gare, 69002 Lyon, and provides information on voting procedures.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-ordinary-extraordinary-general-meeting-170000932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ALD","PXXLF"],"gpt_icon":0},{"id":"2505387092","title":"Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2505387092","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505387092?lang=en_us&edition=fundamental","pubTime":"2025-01-21 01:00","pubTimestamp":1737392400,"startTime":"0","endTime":"0","summary":"Patent life covering Imeglimin in China extended to 2039. Ongoing partnership discussions to develop and market Imeglimin in China, the world's second largest type 2 diabetes market. POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic disorders, today announced that China's National Intellectual Property Administration  has granted Poxel patent ZL201980015603.X for Imeglimin, a first-in-class drug targeting mitochondrial dysfunction and marketed in Japan for the treatment of type-2 diabetes.This new patent protects the use of Imeglimin for type-2 diabetic patients with moderate to severe renal impairment until 2039. The granting of the patent further supports ongoing discussions initiated by Poxel to develop and market Imeglimin in China, following the Company's recovery of the rights to this product in Asian coun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-announces-grant-patent-china-170000878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ALD","PXXLF"],"gpt_icon":0},{"id":"2502060974","title":"Great week for Ampol Limited (ASX:ALD) institutional investors after losing 14% over the previous year","url":"https://stock-news.laohu8.com/highlight/detail?id=2502060974","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502060974?lang=en_us&edition=fundamental","pubTime":"2025-01-09 13:49","pubTimestamp":1736401778,"startTime":"0","endTime":"0","summary":"Key Insights Significantly high institutional ownership implies Ampol's stock price is sensitive to their trading...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/great-week-for-ampol-limited-asxald-institutional-investors","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7065","ALD","ALD.AU"],"gpt_icon":0},{"id":"2502369590","title":"Adisyn acquires 2D Generation, forging foothold in booming semiconductor market","url":"https://stock-news.laohu8.com/highlight/detail?id=2502369590","media":"Stockheads","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502369590?lang=en_us&edition=fundamental","pubTime":"2025-01-09 09:50","pubTimestamp":1736387402,"startTime":"0","endTime":"0","summary":"Adisyn completes the 100% acquisition of semiconductor IP business 2D Generation. 2D Generation’s founder and CEO Arye Kohavi will join the board as a non-executive director. 2D Generation’s IP considered an important advancement in semiconductor technology","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/01/2025-1-9-AI1-NM-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/01/2025-1-9-AI1-NM-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/tech/adisyn-acquires-2d-generation-forging-foothold-in-booming-semiconductor-market/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["ALD"],"gpt_icon":0},{"id":"2502894300","title":"Ampol (ASX:ALD) Might Have The Makings Of A Multi-Bagger","url":"https://stock-news.laohu8.com/highlight/detail?id=2502894300","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502894300?lang=en_us&edition=fundamental","pubTime":"2025-01-09 05:42","pubTimestamp":1736372560,"startTime":"0","endTime":"0","summary":"If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two trends; firstly a growing return on capital employed  and secondly, an increasing amount of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. So on that note, Ampol  looks quite promising in regards to its trends of return on capital.Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income  a company earns on the capital invested in its business. To calculate this metric for Ampol, this is the formula:. Return on Capital Employed = Earnings Before Interest and Tax  ÷ . So, Ampol has an ROCE of 17%.  In absolute terms, that's a satisfactory return, but compared to the Oil and Gas industry average of 9.5% it's much better.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ampol-asx-ald-might-makings-214240168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["EBIT","BK7065","ALD","ALD.AU"],"gpt_icon":0},{"id":"2501239216","title":"Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239216","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239216?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168400,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Jan.  06, 2025  (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/06/3004535/0/en/Tempest-Receives-Orphan-Drug-Designation-from-the-U-S-Food-and-Drug-Administration-for-Amezalpat-to-Treat-Patients-with-Hepatocellular-Carcinoma-HCC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HR","BK4097","BK4183","BK4225","ODD","OS","BK4203","ALD","BK4006","HCC"],"gpt_icon":0},{"id":"2493878987","title":"Availability of Poxel’s 2024 Half-Year Financial Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2493878987","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493878987?lang=en_us&edition=fundamental","pubTime":"2024-12-23 14:30","pubTimestamp":1734935400,"startTime":"0","endTime":"0","summary":"POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic disorders, today announced the availability of its half-year financial report as of June 30, 2024.the condensed consolidated financial statements for the first half of 2024, as of June 30, 2024;the certification of the person responsible for the half-year financial report;the Statutory Auditors’ limited review report on the half-year financial information, which includes an inability to reach a conclusion due to the uncertainties surrounding going concern.NewCapNicolas Fossiez, Aurélie Manavarere / Arthur Rouilléinvestor@poxelpharma.com +33 1 44 71 94 94","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YFMsBG4m_4JzyeRPEgv5VQ--~B/aD0yNTY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/22ee2ffdb7b9679491e16f9db553cdba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YFMsBG4m_4JzyeRPEgv5VQ--~B/aD0yNTY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/22ee2ffdb7b9679491e16f9db553cdba"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/availability-poxel-2024-half-financial-063000943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ALD","PXXLF"],"gpt_icon":0},{"id":"2492771167","title":"Adisyn completes due diligence of  2D Generation, set to tap into hot semiconductor market","url":"https://stock-news.laohu8.com/highlight/detail?id=2492771167","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492771167?lang=en_us&edition=fundamental","pubTime":"2024-12-19 10:09","pubTimestamp":1734574183,"startTime":"0","endTime":"0","summary":"2DG’s graphene breakthrough could transform semiconductors. It could also potentially solve the “holy grail” problem in this space","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/12/Adisyn-completes-due-diligence-for-2DG-acquisition.-Picture-via-Getty-Images-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/12/Adisyn-completes-due-diligence-for-2DG-acquisition.-Picture-via-Getty-Images-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/tech/adisyn-completes-due-diligence-of-2d-generation-set-to-tap-into-hot-semiconductor-market/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["LU1861215975.USD","TSEM","LU1861220033.SGD","BK4141","ALD"],"gpt_icon":0},{"id":"2490008026","title":"ACM Research Strengthens Atomic Layer Deposition Portfolio with Qualification of Thermal and Plasma-Enhanced ALD Furnace Tools","url":"https://stock-news.laohu8.com/highlight/detail?id=2490008026","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490008026?lang=en_us&edition=fundamental","pubTime":"2024-12-11 05:05","pubTimestamp":1733864700,"startTime":"0","endTime":"0","summary":"Thermal and Plasma-Enhanced ALD furnace tools qualified for high-volume 300mm semiconductor manufacturingFREMONT, Calif., Dec.  10, 2024  (GLOBE NEWSWIRE) -- ACM Research, Inc. (“ACM”) (NASDAQ: ACMR),","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/10/2994951/0/en/ACM-Research-Strengthens-Atomic-Layer-Deposition-Portfolio-with-Qualification-of-Thermal-and-Plasma-Enhanced-ALD-Furnace-Tools.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0433182093.SGD","LU0985489474.SGD","LU1489326972.SGD","LU0878866978.SGD","ALD","LU0130102774.USD","LU0320765489.SGD","BK4516","WIW","BK4129","BK4147","BK4505","ACM","LU0068578508.USD","LU0980610538.SGD","LU0648001328.SGD","WTW","BK4588","BK4585","BK4575","LU0070302665.USD","BK4173","ACMR","LU0208291251.USD","LU2308191902.HKD","LU1201861249.SGD","LU0211331839.USD"],"gpt_icon":0},{"id":"2489017141","title":"Returns At Ampol (ASX:ALD) Are On The Way Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2489017141","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489017141?lang=en_us&edition=fundamental","pubTime":"2024-12-05 04:15","pubTimestamp":1733343323,"startTime":"0","endTime":"0","summary":"If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/returns-at-ampol-asxald-are-on-the-way-up","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALD","BK7065","EBIT","ALD.AU"],"gpt_icon":0},{"id":"2489426851","title":"Are Ampol Limited's (ASX:ALD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489426851","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489426851?lang=en_us&edition=fundamental","pubTime":"2024-12-05 04:02","pubTimestamp":1733342534,"startTime":"0","endTime":"0","summary":"With its stock down 3.6% over the past week, it is easy to disregard Ampol . However, the company's fundamentals look pretty decent, and long-term financials are usually aligned with future market price movements. In this article, we decided to focus on Ampol's  ROE.Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital.So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or \"retains\", and how effectively it does so, we are then able to assess a company’s earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.Ampol's significant three-year median","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e.IpaZewPo.hd3eYQKrUAg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/6a7f02cc41eea4ccf3459d0f6858bc42","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e.IpaZewPo.hd3eYQKrUAg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/6a7f02cc41eea4ccf3459d0f6858bc42"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ampol-limiteds-asx-ald-fundamentals-200214210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ALD","ALD.AU","BK7065"],"gpt_icon":0},{"id":"2487958334","title":"Poxel Announces Results from November 28, 2024 Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2487958334","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487958334?lang=en_us&edition=fundamental","pubTime":"2024-11-29 14:30","pubTimestamp":1732861800,"startTime":"0","endTime":"0","summary":"POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic disorders, today announces that it held its Annual General Meeting on November 28, 2024, at 9;00 am CET at the Mercure Lyon Centre Chteau Perrache Hotel, located at 12 Cours de Verdun-Rambaud Esplanade de la Gare, 69002 Lyon, France.The number of voting rights held by shareholders present or represented was 20,270,242, representing a quorum of 37.86%.Details on the voting results, a replay of the Annual General Meeting as well as the presentation that was made during the meeting, are available today on the Company’s website, in the Investors / Shareholder Info / Annual General Meeting Documents section.The resolutions recommended by the Board of Directors related to the 2023 financial statements’ approval and to the renewal of Richard Kender as Director of the Bo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LFBPcRMYHOvlC.CChUWcBA--~B/aD0yNTY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ffc570940941b64768ef3266a1e3f562","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LFBPcRMYHOvlC.CChUWcBA--~B/aD0yNTY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ffc570940941b64768ef3266a1e3f562"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-announces-results-november-28-063000763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALD","BK4139","PXXLF"],"gpt_icon":0},{"id":"2486780136","title":"Adisyn’s 2D Generation is in the global race to bring graphene into advanced semiconductors","url":"https://stock-news.laohu8.com/highlight/detail?id=2486780136","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486780136?lang=en_us&edition=fundamental","pubTime":"2024-11-28 04:50","pubTimestamp":1732740648,"startTime":"0","endTime":"0","summary":"Adisyn’s acquisition of 2DG unlocks semiconductor potential. Graphene breakthrough opens the door for next-gen chips. 2DG’s low-temp graphene process tackles industry bottleneck","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/11/Adisyns-2D-Generation-is-in-the-race-to-bring-graphene-into-semiconductors.-Picture-via-Getty-Images-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/11/Adisyns-2D-Generation-is-in-the-race-to-bring-graphene-into-semiconductors.-Picture-via-Getty-Images-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/tech/adisyns-2d-generation-is-in-the-global-race-to-bring-graphene-into-advanced-semiconductors/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["ALD"],"gpt_icon":0},{"id":"2481941318","title":"Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents","url":"https://stock-news.laohu8.com/highlight/detail?id=2481941318","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481941318?lang=en_us&edition=fundamental","pubTime":"2024-11-07 14:30","pubTimestamp":1730961000,"startTime":"0","endTime":"0","summary":"POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic disorders, today informs its shareholders that the Annual General Meeting  will be held on November 28, 2024, at the Mercure Lyon Centre Chteau Perrache Hotel, located at 12 Cours de Verdun-Rambaud Esplanade de la Gare, 69002 Lyon, and provides information on voting procedures.Shareholders willing to follow the AGM but unable to attend in person are invited to connect via the following link : click here.This live broadcast of the AGM will not allow remote voting or questions via the chat feature on the platform used.The option to vote or grant proxy electronically is available via the secure voting platform Votacess, which will open on November 13, 2024, at 9:00 am  and close on November 27, 2024, at 3:00 pm .For any questions regarding voting procedures, you may","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b903Bbc2XcidD2rWFT.kjg--~B/aD0yNTY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e1aaf02a50fc07c1341077303e4f97ab","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b903Bbc2XcidD2rWFT.kjg--~B/aD0yNTY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e1aaf02a50fc07c1341077303e4f97ab"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-announces-annual-general-meeting-063000461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALD","AGM","BK4229","BK4195","CET","BK4139","PXXLF"],"gpt_icon":0},{"id":"2481293597","title":"Press Release: Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481293597","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481293597?lang=en_us&edition=fundamental","pubTime":"2024-11-07 01:20","pubTimestamp":1730913600,"startTime":"0","endTime":"0","summary":"-- TWYMEEG sales continue to increase in Japan for the last quarter.  by 5% over the prior quarter and by 23% over the 3rd. -- Poxel expects TWYMEEG net sales in Japan in the near term to reach at. least JPY 5 billion 1 entitling the Company to receive. 10% royalties on all TWYMEEG net sales and a sales-based payment of. -- Continued discussions with potential partners in parallel of reviewing. the clinical development strategy for PXL770 and PXL065 for the treatment. extension until end of 2025, including the full residual drawdown of the. -- For the quarter ended September 2024, TWYMEEG gross sales in Japan. -- During Sumitomo Pharma FY 2024, Poxel expects TWYMEEG net sales in. Poxel to receive 10% royalties on all TWYMEEG net sales and a. sales-based payment of JPY 500 million 1. Based on the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD","BK4232","R","BK4022"],"gpt_icon":0},{"id":"2479897770","title":"This High-Flying Stock Just Became a Better Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2479897770","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479897770?lang=en_us&edition=fundamental","pubTime":"2024-10-31 17:45","pubTimestamp":1730367900,"startTime":"0","endTime":"0","summary":"It might not be too late to get in on the party.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795327%2Fpatient-self-administering-a-shot.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795327%2Fpatient-self-administering-a-shot.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/10/31/this-high-flying-stock-just-became-a-better-buy/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["ALD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-02-19","symbol":"ALD","amount":0.075,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1550552400000},{"market":"US","date":"2019-01-22","symbol":"ALD","amount":0.095,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1548133200000},{"market":"US","date":"2018-12-24","symbol":"ALD","amount":0.1,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1545627600000},{"market":"US","date":"2018-11-20","symbol":"ALD","amount":0.1,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1542690000000},{"market":"US","date":"2018-10-23","symbol":"ALD","amount":0.09,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1540267200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALD\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-23","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-02-17","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-03-27","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-05-22","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-06-26","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALD\",market:\"US\",delay:false,,,undefined,":{}}}